21 Apr Quintessence presents at cancer meeting
MADISON AND DENVER – Dr. Laura Strong of Quintessence Biosciences Inc. presented information about one of the company’s EVade Ribonuclease development programs at the annual meeting of the American Association for Cancer Research. Strong presented data from conjugates produced using the clinical candidate QBI-139 and polyethylene glycol (PEG).
QBI-139 is a potent anticancer agent based on the company’s EVade Ribonuclease technology. The technology provides an opportunity to attack RNA, an exciting new drug target, in cancer cells with analogs of the human pancreatic ribonuclease 1. In preclinical disease models, QBI-139 has shown a strong tolerability profile and outstanding tumor growth inhibition in vivo against human pancreatic, non-small cell lung, prostate, and ovarian solid tumors. QBI-139 is currently in a solid tumors Phase I human clinical trial being conducted at the University of Wisconsin Madison Comprehensive Cancer Center.
“The success of the next generation of Evade Ribonuclease products significantly broadens the potential impact of our technology,” said Quintessence Biosciences CEO Ralph Kauten. “Conjugates of EVade Ribonucleases provide a means to extend the utility of a clinically validated approach to cancer treatment.”
Quintessence Biosciences is a private biopharmaceutical company focused on development of proprietary cancer therapies